Illumina Ventures and Section 32 co-led the non-invasive prenatal test maker's $17.1m round, which featured Alexandria Real Estate Equities.
US-based prenatal testing technology developer Cradle Genomics yesterday picked up $17.1m in series A round co-led by Illumina Ventures, the corporate venturing subsidiary of biotechnology developer Illumina.
Section 32 co-led the round, which featured life science real estate trust Alexandria Real Estate Equities, Sea Lane Ventures, Listwin Ventures and Axon Ventures.
Cradle Genomics is developing a non-invasive prenatal test (NIPT) that analyses blood from a pregnant person to determine the genetic makeup of a foetus, helping to detect certain genetic…
